Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands.
Leiden University Medical Center, Einthovenweg 20, 2300 RC Leiden, The Netherlands; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden node, The Netherlands.
Trends Biotechnol. 2023 Aug;41(8):1000-1012. doi: 10.1016/j.tibtech.2023.03.004. Epub 2023 Mar 30.
Clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas)-mediated genome editing has revolutionized biomedical research and will likely change the therapeutic and diagnostic landscape. However, CRISPR-Cas9, which edits DNA by activating DNA double-strand break (DSB) repair pathways, is not always sufficient for gene therapy applications where precise mutation repair is required. Prime editing, the latest revolution in genome-editing technologies, can achieve any possible base substitution, insertion, or deletion without the requirement for DSBs. However, prime editing is still in its infancy, and further development is needed to improve editing efficiency and delivery strategies for therapeutic applications. We summarize latest developments in the optimization of prime editor (PE) variants with improved editing efficiency and precision. Moreover, we highlight some potential therapeutic applications.
成簇规律间隔短回文重复相关蛋白 9 (CRISPR-Cas) 介导的基因组编辑彻底改变了生物医学研究,可能会改变治疗和诊断领域的格局。然而,CRISPR-Cas9 通过激活 DNA 双链断裂 (DSB) 修复途径来编辑 DNA,在需要精确突变修复的基因治疗应用中并不总是足够的。Prime 编辑是基因组编辑技术的最新革命,可以在不产生 DSB 的情况下实现任何可能的碱基替换、插入或缺失。然而,Prime 编辑仍处于起步阶段,需要进一步发展以提高编辑效率和治疗应用的递送策略。我们总结了提高编辑效率和精度的 Prime 编辑器 (PE) 变体的最新优化进展。此外,我们还强调了一些潜在的治疗应用。